| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 16:26 | Stevanato (STVN) Declined Due to Anticipation of Soft Quarter Ahead | ||
| 16:26 | Here's Why uniQure (QURE) Fell in Q3 | ||
| 16:26 | Nebius Group N.V. (NBIS) Slid Along with Broader Selloff of AI Infrastructure-Related Equities | ||
| 16:26 | Natera (NTRA) Surged as Results Beat Expectations | ||
| 14:26 | What Makes Mattel (MAT) a Fundamentally Strong Company? | ||
| 14:26 | Longleaf Partners Fund Sold HF Sinclair Corporation (DINO) at a Profit | ||
| 14:26 | Revenue Resilience Is the New Growth Story in Global Digital Entertainment | ||
| 14:26 | Meta (META) Proceeded to Compound on Its 13%-15% Growth Trajectory | ||
| 14:26 | Mettler-Toledo (MTD) Rebound Shows Strength to Weather Challenges | ||
| 14:26 | Apple (AAPL) Continued to Rebound in Q4 | ||
| 14:26 | XXKK Crypto Exchange Strengthens Platform Transparency and User Communication | ||
| 13:26 | Qnity (Q) "is a Very Inexpensive Stock," Says Jim Cramer | ||
| 13:26 | "Rubrik (RBRK) is One of the Hottest Tech Companies," Says Jim Cramer | ||
| 13:26 | Jim Cramer Just Can't Stop Praising Johnson & Johnson (JNJ) | ||
| 13:26 | Morgan Stanley (MS)'s CEO is Doing a Great Job, Says Jim Cramer | ||
| 13:26 | "Winner Winner, Chicken Dinner," Says Jim Cramer About BlackRock (BLK) | ||
| 13:26 | Bank of America (BAC) Needs Higher Rates, Says Jim Cramer | ||
| 13:26 | Wells Fargo (WFC) "Came in Way Too Hot," Says Jim Cramer | ||
| 13:26 | Jim Cramer Shares Trading Strategy For Goldman Sachs (GS)'s Shares | ||
| 13:26 | Jim Cramer Points Out Split in Salesforce (CRM)'s Business | ||
| 12:26 | Genmab A/S (GMAB) Shares Gain Analyst Support as Deutsche Bank Sees Oncology Upside | ||
| 12:26 | Novartis AG (NVS) Advances $23B U.S. Investment Plan With New RLT Logistics Hub | ||
| 12:26 | Exelixis, Inc. (EXEL) Sees Mixed Analyst Actions as Zanzalintinib Nears Commercial Launch | ||
| 12:26 | Nuvation Bio Inc. (NUVB) Price Target Lowered as IBTROZI Sales Meet Expectations | ||
| 12:26 | AstraZeneca PLC (AZN) Gains After Successful Saphnelo Trial |